Liraglutide and dulaglutide, known as GLP-1 receptor agonists, are currently used to treat type-II diabetes and have been shown to protect against cardiac disease induced by diabetes mellitus 27, 28. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.